197 related articles for article (PubMed ID: 33490264)
1. Data-Driven Discovery of Molecular Targets for Antibody-Drug Conjugates in Cancer Treatment.
Razzaghdoust A; Rahmatizadeh S; Mofid B; Muhammadnejad S; Parvin M; Torbati PM; Basiri A
Biomed Res Int; 2021; 2021():2670573. PubMed ID: 33490264
[TBL] [Abstract][Full Text] [Related]
2. Computational selection of antibody-drug conjugate targets for breast cancer.
Fauteux F; Hill JJ; Jaramillo ML; Pan Y; Phan S; Famili F; O'Connor-McCourt M
Oncotarget; 2016 Jan; 7(3):2555-71. PubMed ID: 26700623
[TBL] [Abstract][Full Text] [Related]
3. Antibody-Drug Conjugates: A Review on the Epitome of Targeted Anti- Cancer Therapy.
Hasan M; Alam S; Poddar SK
Curr Clin Pharmacol; 2018; 13(4):236-251. PubMed ID: 30073930
[TBL] [Abstract][Full Text] [Related]
4. ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery.
Saei AA; Beusch CM; Chernobrovkin A; Sabatier P; Zhang B; Tokat ÜG; Stergiou E; Gaetani M; Végvári Á; Zubarev RA
Nat Commun; 2019 Dec; 10(1):5715. PubMed ID: 31844049
[TBL] [Abstract][Full Text] [Related]
5. Prospects and progress of antibody-drug conjugates in solid tumor therapies.
Govindan SV; Sharkey RM; Goldenberg DM
Expert Opin Biol Ther; 2016 Jul; 16(7):883-93. PubMed ID: 27045979
[TBL] [Abstract][Full Text] [Related]
6. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
7. canSAR: update to the cancer translational research and drug discovery knowledgebase.
Mitsopoulos C; Di Micco P; Fernandez EV; Dolciami D; Holt E; Mica IL; Coker EA; Tym JE; Campbell J; Che KH; Ozer B; Kannas C; Antolin AA; Workman P; Al-Lazikani B
Nucleic Acids Res; 2021 Jan; 49(D1):D1074-D1082. PubMed ID: 33219674
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates.
Kamath AV; Iyer S
Pharm Res; 2015 Nov; 32(11):3470-9. PubMed ID: 25446773
[TBL] [Abstract][Full Text] [Related]
9. Quantitative Proteomic Verification of Membrane Proteins as Potential Therapeutic Targets Located in the 11q13 Amplicon in Cancers.
Hoover H; Li J; Marchese J; Rothwell C; Borawoski J; Jeffery DA; Gaither LA; Finkel N
J Proteome Res; 2015 Sep; 14(9):3670-9. PubMed ID: 26151158
[TBL] [Abstract][Full Text] [Related]
10. Fate of Antibody-Drug Conjugates in Cancer Cells.
Chalouni C; Doll S
J Exp Clin Cancer Res; 2018 Feb; 37(1):20. PubMed ID: 29409507
[TBL] [Abstract][Full Text] [Related]
11. Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy.
Amoedo ND; Obre E; Rossignol R
Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):674-685. PubMed ID: 28213330
[TBL] [Abstract][Full Text] [Related]
12. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
[TBL] [Abstract][Full Text] [Related]
13. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates.
Jackson D; Stover D
Pharm Res; 2015 Nov; 32(11):3458-69. PubMed ID: 25339341
[TBL] [Abstract][Full Text] [Related]
14. The antibody-drug conjugate target landscape across a broad range of tumour types.
Moek KL; de Groot DJA; de Vries EGE; Fehrmann RSN
Ann Oncol; 2017 Dec; 28(12):3083-3091. PubMed ID: 29045509
[TBL] [Abstract][Full Text] [Related]
15. Integrative oncoproteomics strategies for anticancer drug discovery.
Liu R; Wang K; Yuan K; Wei Y; Huang C
Expert Rev Proteomics; 2010 Jun; 7(3):411-29. PubMed ID: 20536311
[TBL] [Abstract][Full Text] [Related]
16. Cryptophycin-55/52 based antibody-drug conjugates: Synthesis, efficacy, and mode of action studies.
Lai Q; Wu M; Wang R; Lai W; Tao Y; Lu Y; Wang Y; Yu L; Zhang R; Peng Y; Jiang X; Fu Y; Wang X; Zhang Z; Guo C; Liao W; Zhang Y; Kang T; Chen H; Yao Y; Gou L; Yang J
Eur J Med Chem; 2020 Aug; 199():112364. PubMed ID: 32402935
[TBL] [Abstract][Full Text] [Related]
17. Conjugation of anticancer drugs through endogenous monoclonal antibody cysteine residues.
Lyon RP; Meyer DL; Setter JR; Senter PD
Methods Enzymol; 2012; 502():123-38. PubMed ID: 22208984
[TBL] [Abstract][Full Text] [Related]
18. Chemical proteomic strategies for the discovery and development of anticancer drugs.
Liu Y; Guo M
Proteomics; 2014 Mar; 14(4-5):399-411. PubMed ID: 24323546
[TBL] [Abstract][Full Text] [Related]
19. Safety and Tolerability of Antibody-Drug Conjugates in Cancer.
Wolska-Washer A; Robak T
Drug Saf; 2019 Feb; 42(2):295-314. PubMed ID: 30649747
[TBL] [Abstract][Full Text] [Related]
20. Antibody-Drug Conjugates.
Kulkarni AA; Gukasyan HJ
Pharm Res; 2015 Nov; 32(11):3451-2. PubMed ID: 26275530
[No Abstract] [Full Text] [Related]
[Next] [New Search]
